Announcements Trials
Browse Landscape

Phase

Phase 2 22Phase 1 11Phase 3 8Phase 1/2 7Phase NA 2Phase EARLY_PHASE1 2Phase 4 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Leukemia 1

Interventions

Magnetic Resonance Spectroscopy 59Cyclophosphamide 44pembrolizumab 34Radiotherapy 30fludarabine 27Nivolumab 26Biopsy 26Metformin 22Fluorodeoxyglucose F18 22Specimen Handling 20Bevacizumab 20Temozolomide 17Radiosurgery 17Cisplatin 16Carboplatin 14Fluorouracil 13Dexamethasone 13Paclitaxel 12Gemcitabine 12Etoposide 12gallium 68 PSMA-11 11durvalumab 11X-Rays 11Surgical Procedures, Operative 11Radiation 11Positron Emission Tomography Computed Tomography 11Letrozole 11Irinotecan 11Ipilimumab 11Surveys and Questionnaires 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × OTHER × Introns × Clear all
NCT03599453 2023-07-18

Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer

Roswell Park Cancer Institute

Phase EARLY_PHASE1 Completed
8 enrolled
Breast

Triple Negative Breast Neoplasms

NCT02331706 2020-04-21

IFN-DLI for Relapsed Acute Leukemia After Allo-SCT

Abramson Cancer Center at Penn Medicine

Phase EARLY_PHASE1 Completed
16 enrolled
Other hematologic neoplasm

Leukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡